Oncology Drugs Market Opportunities 2031
In the recent years, the increased developments in pharmaceutical industry continue to make cancer more treatable. The rising prevalence of cancer led to rise in demand for cancer drugs worldwide. The oncology drugs are used in the diagnosis of cancer depends upon the stages of the progression. Different types of cancer such as, endocrine cancer, blood cancer, lung cancer, skin cancer, bone cancer, genitourinary cancer, breast cancer, gastrointestinal cancer, head & neck cancer, eye cancer and gynaecologic cancer can be treated by oncology drugs.
MARKET DYNAMICS
The oncology drugs market is anticipated to grow in the forecast period owing to driving factors such as, increasing demand for oncology medications worldwide, growing research activities in cancer diagnosis and rising demand for personalized medicines. Moreover, the worldwide growing geriatric population is anticipated to offer more growth opportunities for the players operating in the oncology drugs market.
MARKET SCOPE
The "Global Oncology Drugs Market Analysis to 2031" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of oncology drugs market with detailed market segmentation by drug class type, indication and geography. The global oncology drugs market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading oncology drugs market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The global oncology drugs market is segmented on the basis of drug class type and indication. Based on drug class type, the market is segmented as, chemotherapy, targeted therapy, immunotherapy (biologic therapy) and hormonal therapy. On the basis of indication, the global oncology drugs market is segmented as, lung cancer, stomach cancer, colorectal cancer, breast cancer, prostate cancer, liver cancer, esophagus cancer, cervical cancer, kidney cancer, bladder cancer and others.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global oncology drugs market based on various segments. It also provides market size and forecast estimates from year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The oncology drugs market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting oncology drugs market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the oncology drugs market in these regions.
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global oncology drugs market based on various segments. It also provides market size and forecast estimates from year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The oncology drugs market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting oncology drugs market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the oncology drugs market in these regions.
MARKET PLAYERS
The reports cover key developments in the oncology drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from oncology drugs market are anticipated to lucrative growth opportunities in the future with the rising demand for oncology drugs market in the global market. Below mentioned is the list of few companies engaged in the oncology drugs market.
The report also includes the profiles of key oncology drugs market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
• Pfizer Inc.
• Merck & Co., Inc.
• JOHNSON & JOHNSON (Janssen Global Services, LLC)
• Novartis AG
• F. Hoffmann-La Roche Ltd
• Bristol-Myers Squibb Company
• AstraZeneca
• AbbVie Inc.
• Astellas Pharma Inc.
• CELGENE CORPORATION
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Oncology Drugs Market - By Drug Class Type
1.3.2 Oncology Drugs Market - By Indication
1.3.3 Oncology Drugs Market - By Region
1.3.3.1 By Country
2. KEY TAKEWAYS
3. RESEARCH METHODOLOGY
4. ONCOLOGY DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. ONCOLOGY DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
6. ONCOLOGY DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. ONCOLOGY DRUGS - GLOBAL MARKET OVERVIEW
6.2. ONCOLOGY DRUGS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. ONCOLOGY DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - DRUG CLASS TYPE
7.1. OVERVIEW
7.2. DRUG CLASS TYPE MARKET FORECASTS AND ANALYSIS
7.3. CHEMOTHERAPY
7.3.1. Overview
7.3.2. Chemotherapy Market Forecast and Analysis
7.4. TARGETED THERAPY
7.4.1. Overview
7.4.2. Targeted Therapy Market Forecast and Analysis
7.5. IMMUNOTHERAPY (BIOLOGIC THERAPY)
7.5.1. Overview
7.5.2. Immunotherapy (Biologic Therapy) Market Forecast and Analysis
7.6. HORMONAL THERAPY
7.6.1. Overview
7.6.2. Hormonal Therapy Market Forecast and Analysis
8. ONCOLOGY DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - INDICATION
8.1. OVERVIEW
8.2. INDICATION MARKET FORECASTS AND ANALYSIS
8.3. LUNG CANCER
8.3.1. Overview
8.3.2. Lung Cancer Market Forecast and Analysis
8.4. STOMACH CANCER
8.4.1. Overview
8.4.2. Stomach Cancer Market Forecast and Analysis
8.5. COLORECTAL CANCER
8.5.1. Overview
8.5.2. Colorectal Cancer Market Forecast and Analysis
8.6. BREAST CANCER
8.6.1. Overview
8.6.2. Breast Cancer Market Forecast and Analysis
8.7. PROSTATE CANCER
8.7.1. Overview
8.7.2. Prostate Cancer Market Forecast and Analysis
8.8. LIVER CANCER
8.8.1. Overview
8.8.2. Liver Cancer Market Forecast and Analysis
8.9. ESOPHAGUS CANCER
8.9.1. Overview
8.9.2. Esophagus Cancer Market Forecast and Analysis
8.10. CERVICAL CANCER
8.10.1. Overview
8.10.2. Cervical Cancer Market Forecast and Analysis
8.11. KIDNEY CANCER
8.11.1. Overview
8.11.2. Kidney Cancer Market Forecast and Analysis
8.12. BLADDER CANCER
8.12.1. Overview
8.12.2. Bladder Cancer Market Forecast and Analysis
8.13. OTHERS
8.13.1. Overview
8.13.2. Others Market Forecast and Analysis
9. ONCOLOGY DRUGS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Oncology Drugs Market Overview
9.1.2 North America Oncology Drugs Market Forecasts and Analysis
9.1.3 North America Oncology Drugs Market Forecasts and Analysis - By Drug Class Type
9.1.4 North America Oncology Drugs Market Forecasts and Analysis - By Indication
9.1.5 North America Oncology Drugs Market Forecasts and Analysis - By Countries
9.1.5.1 United States Oncology Drugs Market
9.1.5.1.1 United States Oncology Drugs Market by Drug Class Type
9.1.5.1.2 United States Oncology Drugs Market by Indication
9.1.5.2 Canada Oncology Drugs Market
9.1.5.2.1 Canada Oncology Drugs Market by Drug Class Type
9.1.5.2.2 Canada Oncology Drugs Market by Indication
9.1.5.3 Mexico Oncology Drugs Market
9.1.5.3.1 Mexico Oncology Drugs Market by Drug Class Type
9.1.5.3.2 Mexico Oncology Drugs Market by Indication
9.2. EUROPE
9.2.1 Europe Oncology Drugs Market Overview
9.2.2 Europe Oncology Drugs Market Forecasts and Analysis
9.2.3 Europe Oncology Drugs Market Forecasts and Analysis - By Drug Class Type
9.2.4 Europe Oncology Drugs Market Forecasts and Analysis - By Indication
9.2.5 Europe Oncology Drugs Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Oncology Drugs Market
9.2.5.1.1 Germany Oncology Drugs Market by Drug Class Type
9.2.5.1.2 Germany Oncology Drugs Market by Indication
9.2.5.2 France Oncology Drugs Market
9.2.5.2.1 France Oncology Drugs Market by Drug Class Type
9.2.5.2.2 France Oncology Drugs Market by Indication
9.2.5.3 Italy Oncology Drugs Market
9.2.5.3.1 Italy Oncology Drugs Market by Drug Class Type
9.2.5.3.2 Italy Oncology Drugs Market by Indication
9.2.5.4 Spain Oncology Drugs Market
9.2.5.4.1 Spain Oncology Drugs Market by Drug Class Type
9.2.5.4.2 Spain Oncology Drugs Market by Indication
9.2.5.5 United Kingdom Oncology Drugs Market
9.2.5.5.1 United Kingdom Oncology Drugs Market by Drug Class Type
9.2.5.5.2 United Kingdom Oncology Drugs Market by Indication
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Oncology Drugs Market Overview
9.3.2 Asia-Pacific Oncology Drugs Market Forecasts and Analysis
9.3.3 Asia-Pacific Oncology Drugs Market Forecasts and Analysis - By Drug Class Type
9.3.4 Asia-Pacific Oncology Drugs Market Forecasts and Analysis - By Indication
9.3.5 Asia-Pacific Oncology Drugs Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Oncology Drugs Market
9.3.5.1.1 Australia Oncology Drugs Market by Drug Class Type
9.3.5.1.2 Australia Oncology Drugs Market by Indication
9.3.5.2 China Oncology Drugs Market
9.3.5.2.1 China Oncology Drugs Market by Drug Class Type
9.3.5.2.2 China Oncology Drugs Market by Indication
9.3.5.3 India Oncology Drugs Market
9.3.5.3.1 India Oncology Drugs Market by Drug Class Type
9.3.5.3.2 India Oncology Drugs Market by Indication
9.3.5.4 Japan Oncology Drugs Market
9.3.5.4.1 Japan Oncology Drugs Market by Drug Class Type
9.3.5.4.2 Japan Oncology Drugs Market by Indication
9.3.5.5 South Korea Oncology Drugs Market
9.3.5.5.1 South Korea Oncology Drugs Market by Drug Class Type
9.3.5.5.2 South Korea Oncology Drugs Market by Indication
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Oncology Drugs Market Overview
9.4.2 Middle East and Africa Oncology Drugs Market Forecasts and Analysis
9.4.3 Middle East and Africa Oncology Drugs Market Forecasts and Analysis - By Drug Class Type
9.4.4 Middle East and Africa Oncology Drugs Market Forecasts and Analysis - By Indication
9.4.5 Middle East and Africa Oncology Drugs Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Oncology Drugs Market
9.4.5.1.1 South Africa Oncology Drugs Market by Drug Class Type
9.4.5.1.2 South Africa Oncology Drugs Market by Indication
9.4.5.2 Saudi Arabia Oncology Drugs Market
9.4.5.2.1 Saudi Arabia Oncology Drugs Market by Drug Class Type
9.4.5.2.2 Saudi Arabia Oncology Drugs Market by Indication
9.4.5.3 U.A.E Oncology Drugs Market
9.4.5.3.1 U.A.E Oncology Drugs Market by Drug Class Type
9.4.5.3.2 U.A.E Oncology Drugs Market by Indication
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Oncology Drugs Market Overview
9.5.2 South and Central America Oncology Drugs Market Forecasts and Analysis
9.5.3 South and Central America Oncology Drugs Market Forecasts and Analysis - By Drug Class Type
9.5.4 South and Central America Oncology Drugs Market Forecasts and Analysis - By Indication
9.5.5 South and Central America Oncology Drugs Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Oncology Drugs Market
9.5.5.1.1 Brazil Oncology Drugs Market by Drug Class Type
9.5.5.1.2 Brazil Oncology Drugs Market by Indication
9.5.5.2 Argentina Oncology Drugs Market
9.5.5.2.1 Argentina Oncology Drugs Market by Drug Class Type
9.5.5.2.2 Argentina Oncology Drugs Market by Indication
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. ONCOLOGY DRUGS MARKET, KEY COMPANY PROFILES
11.1. ABBVIE INC.
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. ASTELLAS PHARMA INC.
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. ASTRAZENECA PLC
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. BRISTOL-MYERS SQUIBB COMPANY
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. CELGENE CORPORATION
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. F. HOFFMANN-LA ROCHE LTD.
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. JOHNSON AND JOHNSON (JANSSEN GLOBAL SERVICES, LLC,)
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. MERCK AND CO., INC.
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. NOVARTIS AG
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. PFIZER INC.
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
1. Pfizer Inc.
2. Merck & Co., Inc.
3. JOHNSON & JOHNSON (Janssen Global Services, LLC)
4. Novartis AG
5. F. Hoffmann-La Roche Ltd
6. Bristol-Myers Squibb Company
7. AstraZeneca
8. AbbVie Inc.
9. Astellas Pharma Inc.
10. CELGENE CORPORATION
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For